✦ LIBER ✦

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

✍ Scribed by Bray, J; Sludden, J; Griffin, M J; Cole, M; Verrill, M; Jamieson, D; Boddy, A V

Book ID: 110000386
Publisher: Nature Publishing Group
Year: 2010
Tongue: English
Weight: 367 KB
Volume: 102
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6605587

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CBR1 and CBR3 pharmacogenetics and their

CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients

✍ Suman Lal; Edwin Sandanaraj; Zee Wan Wong; Peter C.S. Ang; Nan Soon Wong; Edmund 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 261 KB

Quality of life and toxicity in breast c

Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil)

✍ N. Hatam; N. Ahmadloo; A. Ahmad Kia Daliri; P. Bastani; M. Askarian 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 178 KB

Pharmacokinetics of intravenous etoposid

Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration

✍ Dagmar Busse; Gudrun Würthwein; Christiane Hinske; Georg Hempel; Martin F. Fromm 📂 Article 📅 2002 🏛 Springer-Verlag 🌐 English ⚖ 109 KB

Vincristine, doxorubicin and mitomycin (

Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF)

✍ Sharon K. Shipp; Hyman B. Muss; Mary Alice Westrick; M. Robert Cooper; V. Jackso 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 383 KB

Thirty-six evaluable patients with advanced breast cancer who had failed prior CMF therapy [15 (42%) as adjuvant treatment and 21 (58%) for advanced disease] were treated with a combination of vincristine, doxorubicin, and mitomycin (VAM). There was one CR and 10 PR, giving a response rate of 31% (P

Once-per-cycle pegfilgrastim in breast c

Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide

✍ L. MONTELLA; R. ADDEO; R. GUARRASI; G. CENNAMO; V. FAIOLA; E. CAPASSO; M. CARAGL 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

MRI Phenotype Is Associated With Respons

MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer

✍ Laura Esserman; Elizabeth Kaplan; Savanah Partridge; Debasish Tripathy; Hope Rug 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 882 KB